Ophthalmics Partnering Terms and Agreements, New Report Launched

The Ophthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter ophthalmics partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right t- license the licensors ophthalmics technology. These deals tend t- be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest ophthalmics deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight int- the negotiation process in terms of what you can expect t- achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases d- not.

The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction t- the report.

Chapter 2 provides an overview of the trends in ophthalmics dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                            

Chapter 3 provides a review of the leading ophthalmics deals since 2009 listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access t- the contract.

                                                                      

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of ophthalmics deals, as well as contract documents available in the public domain. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.

Chapter 6 provides comprehensive access t- all ophthalmics deals since 2009 where a deal contract is available, providing the user with direct access t- contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink t- an online version of the deal record contract document, providing easy access t- each contract document on demand.

Chapter 7 provides a comprehensive directory of all ophthalmics partnering deals by specific therapeutic target announced since 2009. The chapter is organized by specific ophthalmics therapeutic target. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all ophthalmics partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.

The report als- includes numerous tables and figures that illustrate the trends and activities in ophthalmics partnering and dealmaking since 2009.                 

                       

In conclusion, this report provides everything a prospective dealmaker needs t- know about partnering in the research, development and commercialization of ophthalmics technologies and products.

Benefits

Ophthalmics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of ophthalmics deal trends since 2009
• Access ophthalmics deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between ophthalmics partner companies
• Comprehensive access t- over 400 links t- actual ophthalmics deals entered int- by the world’s biopharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner ophthalmics opportunities
• Uncover companies actively partnering opthalmics opportunities

Report scope

Ophthalmics Partnering Terms and Agreements is intended t- provide the reader with an in-depth understanding and access t- ophthalmics trends and structure of deals entered int- by leading companies worldwide.

Ophthalmics Partnering Terms and Agreements includes:

• Trends in ophthalmics dealmaking in the biopharma industry since 2009
• Analysis of ophthalmics deal structure
• Access t- headline, upfront, milestone and royalty data
• Access t- hundreds of ophthalmics deal contract documents
• Comprehensive access t- over 400 ophthalmics deal records
• The leading ophthalmics deals by value since 2009
• Most active ophthalmics dealmakers since 2009

In Opthalmics Partnering Terms and Agreements, available deals and contracts are listed by:

• Headline value and opfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.

Spanning over 767 pages, “Ophthalmics Partnering Terms & Agreements” report covering the Executive Summary, Introduction, Trends in ophthalmic dealmaking,  Leading ophthalmic deals, Big pharma ophthalmic deals, Big biotech ophthalmic deals, Ophthalmic partnering contracts directory, Ophthalmic dealmaking by therapeutic target, Appendices. The report covered few companies are - 20/10 Perfect Vision,4SC,AAIPharma Services,Abbott Laboratories,Abbott Medical Optics,Ablynx,Accutome,Aciex Therapeutics,ActiveSite,Activus Pharma,Acucela,Adoptics,Advanced Cell Technology,Advanced Vision Research,Aerie Pharmaceuticals,Aerpio Therapeutics,AGTC,AJL Ophthalmic

For more information see - http://mrr.cm/ZWb

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare